Please wait a minute...
J Zhejiang Univ (Med Sci)  2020, Vol. 49 Issue (2): 240-244    DOI: 10.3785/j.issn.1008-9292.2020.03.08
    
Pregnant women complicated with COVID-19: a clinical analysis of 3 cases
CHEN Xu1(),LI Yang1,*(),WANG Jinxi1,CAI Hongliu2,CAO Hongcui3,SHENG Jifang3
1. Department of Obstetrics and Gynecology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
2. Department of Critical Care Medicine, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
3. Department of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Download: HTML( 21 )   PDF(2811KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: To analyze the clinical characteristics and pregnancy outcomes of pregnant women complicated with coronavirus disease 2019 (COVID-19). Methods: The clinical data of 3 pregnant women with COVID-19 admitted to the First Affiliated Hospital of Zhejiang University School of Medicine from January 19 to February 10, 2020 were retrospectively analyzed. Results: There was one case in the first-trimester pregnancy (case 1), one in the second-trimester pregnancy (case 2) and one in third-trimester pregnancy (case 3). Cough, fever, fatigue, lung imaging changes were the main manifestations. The white cell count, lymphocyte percentage had no significantly changes in case 1 and case 3, while the levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), IL-6 and IL-10 elevated. The lymphocyte count and lymphocyte percentage decreased and the inflammatory indicators significantly increased in case 2. All patients were treated with antiviral, antitussive, oxygen inhalation; case 3 received glucocorticoids, case 2 with severe illness received glucocorticoids and additionally gamma globulin. All three cases were cured and discharged. Case 1 with early pregnancy chose to terminate pregnancy after discharge; case 2 chose to continue pregnancy without obstetric complications; and case 3 had cesarean section delivery due to abnormal fetal heart monitoring. Conclusion: The report shows that COVID-19 in pregnancy women could be cured with active treatment, and the maternal and fetal outcomes can be satisfactory.



Key wordsCoronavirus disease 2019      Severe acute respiratory syndrome coronavirus 2      Novel coronavirus pneumonia      Pregnancy      Pregnancy outcome     
Received: 28 February 2020      Published: 17 March 2020
CLC:  R714.251  
Corresponding Authors: LI Yang     E-mail: 1517009@zju.edu.cn;liyang2014@zju.edu.cn
Cite this article:

CHEN Xu,LI Yang,WANG Jinxi,CAI Hongliu,CAO Hongcui,SHENG Jifang. Pregnant women complicated with COVID-19: a clinical analysis of 3 cases. J Zhejiang Univ (Med Sci), 2020, 49(2): 240-244.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2020.03.08     OR     http://www.zjujournals.com/med/Y2020/V49/I2/240


三例妊娠合并2019冠状病毒病(COVID-19)患者诊治分析

目的: 研究妊娠合并2019冠状病毒病(COVID-19)患者的临床特点及妊娠结局。方法: 对浙江大学医学院附属第一医院2020年1月19日至2月10日收治的3例妊娠合并COVID-19患者的临床表现、辅助检查、治疗经过、妊娠结局进行回顾性分析。结果: 3例患者早孕(例1)、中孕(例2)、晚孕(例3)各1例,例1和例3为COVID-19普通型,例2为COVID-19重型;以咳嗽、发热、乏力、肺部影像学改变为主要表现,例1、例3实验室检查提示白细胞计数、淋巴细胞百分比等无明显变化,炎症指标如C反应蛋白、红细胞沉降率、IL-6、IL-10等轻度升高,例2淋巴细胞计数及淋巴细胞百分比明显降低,炎症因子水平明显升高。3例患者经过抗病毒、止咳、吸氧等综合治疗,其中例2使用糖皮质激素和丙种球蛋白调节免疫治疗,例3使用糖皮质激素,均符合出院标准。例1出院后选择终止妊娠;例2无产科并发症选择继续妊娠;例3因胎心监护异常行剖宫产终止妊娠,母胎情况良好。结论: 妊娠合并COVID-19患者经积极治疗可以痊愈,母胎结局良好,但对子代的影响仍需进一步研究。


关键词: 2019冠状病毒病,  严重急性呼吸综合征冠状病毒2,  新型冠状病毒肺炎,  妊娠,  妊娠结局 
实验室检查项目 正常值范围 例1 例2 例3
  1 mmHg=0.133 kPa.COVID-19:2019冠状病毒病.
白细胞计数(×109/L) 4.0~10.0 5.1 7.5 8.2
中性粒细胞百分比(%) 50~70 61.8 85.2 81.4
淋巴细胞计数(×109/L) 0.8~4.0 1.4 0.4 0.9
淋巴细胞百分比(%) 20~40 26.6 10.8 12.9
红细胞沉降率(mm/1h) 0~20 30 75 34
C反应蛋白(mg/L) 0~10 17 50.95 11.76
IL-6(pg/mL) 0.1~2.9 23.04 458.59 21.93
IL-10(pg/mL) 0.1~5.0 6.66 8.83 7.89
丙氨酸转氨酶(U/L) 7~40 13 17 12
天冬氨酸转氨酶(U/L) 13~35 11 15 17
肌酐(μmol/L) 41~73 64 50 46
呼吸频率(次/min) 16~20 18 25 20
氧分压(mmHg) 80~110 107 90.8 174
氧饱和度(%) 91~99 97 92 97
氧合指数(mmHg) 400~500 462 279 527
Tab 1 Laboratory examination of 3 pregnant patients with COVID-19 at admission
Fig 1 CT findings of 3 pregnant patients with COVID-19 at admission
例序 抗病毒 糖皮质激素 丙种球蛋白 氧疗
  *甲泼尼龙首次40~80 mg/d,症状控制3~4 d后,按1/2~1/3量给药,每3~4 d减1次,逐渐减量,直至停用并酌情改为口服.
例1 阿比多尔200 mg口服,3次/d,共8 d; 洛匹那韦/利托那韦160 mg/40 mg口服,2次/d,共8 d 持续鼻导管吸氧3 L/min,共8 d
例2 洛匹那韦/利托那韦160 mg/40 mg口服,2次/d,共12 d 首次甲泼尼龙80 mg静脉滴注,1次/d* 丙种球蛋白20 g静脉滴注,1次/d,共5 d 持续鼻导管吸氧3 L/min,共16 d
例3 洛匹那韦/利托那韦160 mg/40 mg口服,2次/d,共9 d 首次甲泼尼龙40 mg静脉滴注,1次/d* 鼻导管吸氧3 L/min,每次30 min,3次/d,共10 d
Tab 2 Treatments for 3 pregnant patients with COVID-19 during hospitalization
[1]   WONG S F , CHOW K M , LEUNG T N et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome[J]. Am J Obstet Gynecol, 2004, 191 (1): 292- 297
doi: 10.1016/j.ajog.2003.11.019
[2]   中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第六版)[A/OL].国卫办医涵〔2020〕145号.(2020-02-18)[2020-02-28].http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml.
General Office of National Health Commission of the People's Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment of novel coronavirus pneumonia (trial version 6)[A/OL]. No.145〔2020〕 of the General Office of the National Health Commission. (2020-02-18)[2020-02-28]. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml. (in Chinese)
[3]   LU R , ZHAO X , LI J et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J]. Lancet, 2020, 395 (10224): 565- 574
doi: 10.1016/S0140-6736(20)30251-8
[4]   LAM C M , WONG S F , LEUNG T N et al. A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome[J]. BJOG, 2004, 111 (8): 771- 774
doi: 10.1111/j.1471-0528.2004.00199.x
[1] WANG Jincheng,LIU Jinpeng,WANG Yuanyuan,LIU Wei,CHEN Xiaoqun,SUN Chao,SHEN Xiaoyong,WANG Qidong,WU Yaping,LIANG Wenjie,RUAN Lingxiang. Dynamic changes of chest CT imaging in patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 191-197.
[2] ZHANG Xiaoyan, SUN Wei, SHANG Shiqiang, MAO Jianhua, FU Junfen, SHU Qiang, JIANG Kewen. Principles and suggestions on biosafety protection of biological specimen preservation during prevalence of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 170-177.
[3] CAO Shengli,FENG Peihua,SHI Pengpeng. Study on the epidemic development of COVID-19 in Hubei province by a modified SEIR model[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 178-184.
[4] CHEN Jun,LIU Danping,LIU Li,LIU Ping,XU Qingnian,XIA Lu,LING Yun,HUANG Dan,SONG Shuli,ZHANG Dandan,QIAN Zhiping,LI Tao,SHEN Yinzhong,LU Hongzhou. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 215-219.
[5] CHEN Zhimin,FU Junfen,SHU Qiang,WANG Wei,CHEN Yinghu,HUA Chunzhen,LI Fubang,LIN Ru,TANG Lanfang,WANG Tianlin,WANG Yingshuo,XU Weize,YANG Zihao,YE Sheng,YUAN Tianming,ZHANG Chenmei,ZHANG Yuanyuan. Diagnosis and treatment recommendation for pediatric COVID-19 (the second edition)[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 139-146.
[6] XU Kaijin,CAI Hongliu,SHEN Yihong,NI Qin,CHEN Yu,HU Shaohua,LI Jianping,WANG Huafen,YU Liang,HUANG He,QIU Yunqing,WEI Guoqing,FANG Qiang,ZHOU Jianying,SHENG Jifang,LIANG Tingbo,LI Lanjuan. Management of COVID-19: the Zhejiang experience[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 147-157.
[7] JIANG Saiping,LI Lu,RU Renping,ZHANG Chunhong,RAO Yuefeng,LIN Bin,WANG Rongrong,CHEN Na,WANG Xiaojuan,CAI Hongliu,SHENG Jifang,ZHOU Jianying,LU Xiaoyang,QIU Yunqing. Pharmaceutical care for severe and critically ill patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 158-169.
[8] LI Xin,DAI Tian,WANG Hong,SHI Junnian,YUAN Wei,LI Jing,CHEN Lijun,ZHANG Tianming,ZHANG Shanshan,KONG Yan,YUE Ning,SHI Hui,HE Yuping,HU Huifang,LIU Furong,YANG Caixia. Clinical analysis of suspected COVID-19 patients with anxiety and depression[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 203-208.
[9] LUO Song,YANG Lijuan,WANG Chun,LIU Chuanmiao,LI Dianming. Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 227-231.
[10] HONG Dongsheng,NI Jian,SHAN Wenya,LI Lu,HU Xi,YANG Hongyu,ZHAO Qingwei,ZHANG Xingguo. Establishment of a rapid identification of adverse drug reaction program in R language implementation based on monitoring data[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 253-259.
[11] ZHONG Qi,LI Zhi,SHEN Xiaoyong,XU Kaijin,SHEN Yihong,FANG Qiang,CHEN Feng,LIANG Tingbo. CT imaging features of patients with different clinical types of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 198-202.
[12] KANG Xianhui,ZHANG Rong,HE Huiliang,YAO Yongxing,ZHENG Yueying,WEN Xiaohong,ZHU Shengmei. Anesthesia management in cesarean section for patient with COVID-19: a case report[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 249-252.
[13] SHEN Lihua,HUANG Fei,CHEN Xiang,XIONG Zuan,YANG Xiaoyu,LI Hui,CHENG Feng,GUO Jian,GONG Guofu. Diagnostic efficacy of three test kits for SARS-CoV-2 nucleic acid detection[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 185-190.
[14] ZHAGN Sheng,LI Danping,CHEN Huazhong,ZHENG Dan,ZHOU Yiping,CHEN Baoguo,SHI Weiwu,LIN Ronghai. Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 220-226.
[15] LI Youjiang,HU Yingying,ZHANG Xiaodong,YU Yuanyuan,LI Bin,WU Jianguo,WU Yingping,XIA Xiaoping,XU Jian. Follow-up testing of viral nucleic acid in discharged patients with moderate type of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 270-274.